Genentech slashes nearly 500 jobs in strategic shift to 'local healthcare ecosystems.' Clinical specialists make up the biggest group
Deep into the pandemic, the executives at Roche are executing an unusual plan to lay off nearly 500 workers at South San Francisco-based Genentech.
The huge Roche subsidiary handed in their WARN notice to the state a few days ago, noting that 474 staffers were being permanently cut from the payroll.
A spokesperson for the company told me via e-mail:
The majority of these roles are from our field organization and, though formally associated with our South San Francisco headquarters, are actually located throughout the United States. These position eliminations are not related to the COVID-19 pandemic, the clinical trials for which Actemra is being studied in COVID-19 pneumonia, or any specific therapeutic area.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.